Laurent Poirot

TL;DR: The applicability of TALEN-mediated genome editing to a scalable process enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets and can therefore be used in an "off-the-shelf" manner akin to other biologic immunopharmaceuticals.

TL;DR: This Review analyses the different sources of T cells and technological approaches to produce optimal allogeneic chimeric antigen receptor T cells with limited potential for graft-versus-host disease and increased persistence and describes the different technological approaches.

TL;DR: These alternative approaches based on non-viral vectorization and/or targeted insertion aimed at achieving safer gene transfer are reviewed, with a special emphasis on megan nucleases, a family of naturally occurring rare-cutting endonucleases, and speculate on their current and future potential.

TL;DR: In this article, RNA-guided endonucleases, in particular Cas9/CRISPR system, were used to specifically target a selection of key genes in T-cells for immunotherapy.

TL;DR: This article used rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells.